Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests better comfort care for liver patients

NCT ID NCT03540771

Symptom relief Sponsor: Albert Einstein Healthcare Network Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two approaches to bring palliative care (comfort-focused care) to people with end-stage liver disease. About 1,500 adults from 19 U.S. centers took part. One group had direct access to a palliative care specialist; the other group saw a liver doctor specially trained in palliative care. The main goal was to see if either approach improved quality of life more over three months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,494 people

The number who actually took part.

Started

Jan 2019

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Eligible patients were adults (≥18 years) with: 1. cirrhosis and a decompensation event indicative of ESLD (such as ascites, variceal bleeding or hepatic encephalopathy) within the prior 6 months, or 2. hepatocellular cancer (HCC) except Barcelona Stage D, or multifocal HCC (as defined by standard guidelines and confirmed by treating hepatologist). Additional inclusion criteria included English literacy and the capacity to complete study assessments. Exclusion criteria were hepatologist assessed life expectancy \<6 months, prior liver transplantation, anticipated liver transplantation within 3 months, inability to consent, or receipt of PC within the previous three months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Decompensated cirrhosis of liver are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver End Stage Liver Disease hepatocellular carcinoma pediatric hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Decompensated cirrhosis of liver End-stage liver disease

Contacts and locations

Locations

  • Albert Einstein Medical Center

    Philadelphia, Pennsylvania, 19141, United States

  • Banner Health- University Medical Center

    Phoenix, Arizona, 85006, United States

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • Corporal Michael J. Crescenz VA Medical Center

    Philadelphia, Pennsylvania, 19104, United States

  • Durham V.A. Medical Center

    Durham, North Carolina, 27705, United States

  • Indiana University

    Indianapolis, Indiana, 46202, United States

  • Kansas City VA Medical Center

    Kansas City, Missouri, 64128, United States

  • Loma Linda Unversity Health

    Loma Linda, California, 92354, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Miami VA Medical Center

    Miami, Florida, 33125, United States

  • UCSF Fresno

    Fresno, California, 93701, United States

  • UNC Liver Center

    Chapel Hill, North Carolina, 27599, United States

  • University of Alabama

    Birmingham, Alabama, 35233, United States

  • University of Florida

    Gainesville, Florida, 32611, United States

  • University of Michigan Medical Center

    Ann Arbor, Michigan, 48109, United States

  • VA Boston

    Boston, Massachusetts, 02130, United States

  • VA Bronx

    The Bronx, New York, 10468, United States

  • VA New York Harbor

    Brooklyn, New York, 11209, United States

  • VA West Haven

    West Haven, Connecticut, 06516, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.